Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases

Due to limited investigations about efficacy of tyrosine kinase inhibitors (TKIs) plus immune-checkpoint inhibitors (ICIs) versus TKIs alone, and effects of durations of bone modifying agents (BMAs) on the survival of patients with hepatocellular carcinoma (HCC) and bone metastases (BoM), we aim to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhaoyu, Shen, Zhilong, Wang, Xiang, Wang, Pengru, Zhu, Xiaofei, Fan, Jiefu, Li, Bo, Xu, Wei, Xiao, Jianru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738198/
https://www.ncbi.nlm.nih.gov/pubmed/36498476
http://dx.doi.org/10.3390/jcm11236901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738198/
https://www.ncbi.nlm.nih.gov/pubmed/36498476
http://dx.doi.org/10.3390/jcm11236901

Ejemplares similares